{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:52:13Z","timestamp":1781657533926,"version":"3.54.5"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"JSPS KAKENSHI","award":["21K16332"],"award-info":[{"award-number":["21K16332"]}]},{"DOI":"10.13039\/100007786","name":"National Center for Child Health and Development","doi-asserted-by":"crossref","award":["2025B-8"],"award-info":[{"award-number":["2025B-8"]}],"id":[{"id":"10.13039\/100007786","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>\n                      Valganciclovir (VGCV) is the first-line therapeutic agent for cytomegalovirus (CMV) infection following pediatric liver transplantation (LT). The dosage for pediatric patients is either determined by body weight (BW dose) or body surface area (BSA) and renal function (7 \u00d7 BSA [m\n                      <jats:sup>2<\/jats:sup>\n                      ] \u00d7 creatinine clearance (CrCl) [mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      ]) (BSA dose). However, the optimal dosing strategy for achieving target drug exposure for CMV treatment remains unclear.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>\n                      We conducted a prospective pharmacokinetic study in pediatric LT patients. The area under the concentration-time curve (AUC\n                      <jats:sub>0\u201324<\/jats:sub>\n                      ) was estimated using previously reported pediatric population pharmacokinetic parameters. An AUC\n                      <jats:sub>0\u201324<\/jats:sub>\n                      of 80\u2013120 \u00b5g\u00b7h\/mL was defined as the therapeutic target. The primary endpoint was to compare the achievement rate of target AUC between BW and BSA doses. Although BW dose is the standard at our institution, a hypothetical BSA dose was estimated proportionally for comparison with BW dose.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      Fourteen patients with a median age of 1.1 y were included. The median VGCV dose was 15.3\u2009mg\/kg, whereas the hypothetical median BSA dose was 24.5\u2009mg\/kg. The estimated AUC\n                      <jats:sub>0\u201324<\/jats:sub>\n                      in BW and BSA dose groups were as follows: &lt;80 \u00b5g\u00b7h\/mL, 85.7% and 35.7%; 80\u2013120 \u00b5g\u00b7h\/mL, 14.3% and 42.9%; &gt;120 \u00b5g\u00b7h\/mL, 0.0% and 21.4% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.027). There was a negative correlation between AUC\n                      <jats:sub>0\u201324<\/jats:sub>\n                      and the duration of CMV viremia, indicating that higher AUC values were associated with faster viral clearance (\u03c1 = \u22120.72,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>\n                      Based on our estimation, BSA dosing may be more likely to achieve the target AUC\n                      <jats:sub>0\u201324<\/jats:sub>\n                      compared with BW dosing in infant\/toddler LT recipients. Higher AUC values correlated with faster viral clearance.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/txd.0000000000001964","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:07Z","timestamp":1781654407000},"page":"e1964","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Optimization of Valganciclovir for Treatment of Cytomegalovirus Infection in Pediatric Liver Transplant Recipients: A Prospective Pharmacokinetic Study"],"prefix":"10.1097","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7164-0262","authenticated-orcid":false,"given":"Kensuke","family":"Shoji","sequence":"first","affiliation":[{"name":"Center for Postgraduate Education and Training, National Center for Child Health and Development."},{"name":"Division of Infectious Diseases, National Center for Child Health and Development."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumpei","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Center for Child Health and Development."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Futatsugi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, National Center for Child Health and Development."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Ikuse","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, National Center for Child Health and Development."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketo","family":"Kasai","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, National Center for Child Health and Development."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Matsui","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, National Center for Child Health and Development."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, National Center for Child Health and Development."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Ogimi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, National Center for Child Health and Development."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Uchida","sequence":"additional","affiliation":[{"name":"Center for Organ Transplantation, National Center for Child Health and Development."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinari","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Center for Organ Transplantation, National Center for Child Health and Development."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seisuke","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Center for Organ Transplantation, National Center for Child Health and Development."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mureo","family":"Kasahara","sequence":"additional","affiliation":[{"name":"Center for Organ Transplantation, National Center for Child Health and Development."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"R1-20260616","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1128\/AAC.48.7.2782-2783.2004","article-title":"Pharmacokinetics of oral valganciclovir and intravenous ganciclovir administered to prevent cytomegalovirus disease in an adult patient receiving small-intestine transplantation.","volume":"48","author":"Fort\u00fan Abete","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R2-20260616","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/TP.0000000000005374","article-title":"The Fourth International Consensus guidelines on the management of cytomegalovirus in solid organ transplantation.","volume":"109","author":"Kotton","year":"2025","journal-title":"Transplantation"},{"key":"R3-20260616","doi-asserted-by":"crossref","first-page":"e14493","DOI":"10.1111\/petr.14493","article-title":"Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis.","volume":"27","author":"Liverman","year":"2023","journal-title":"Pediatr Transplant"},{"key":"R4-20260616","doi-asserted-by":"crossref","first-page":"ofae353","DOI":"10.1093\/ofid\/ofae353","article-title":"Multicenter analysis of valganciclovir prophylaxis in pediatric solid organ transplant recipients.","volume":"11","author":"Foca","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"R5-20260616","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1600-6143.2008.02528.x","article-title":"Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients.","volume":"9","author":"Vaudry","year":"2009","journal-title":"Am J Transplant"},{"key":"R6-20260616","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/petr.12030","article-title":"Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients.","volume":"17","author":"Villeneuve","year":"2013","journal-title":"Pediatr Transplant"},{"key":"R7-20260616","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/FTD.0000000000000925","article-title":"Therapeutic drug monitoring of ganciclovir: where are we?","volume":"44","author":"M\u00e4rtson","year":"2022","journal-title":"Ther Drug Monit"},{"key":"R8-20260616","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1097\/TP.0b013e31822d873d","article-title":"A universal preemptive therapy for cytomegalovirus infections in children after live-donor liver transplantation.","volume":"92","author":"Saitoh","year":"2011","journal-title":"Transplantation"},{"key":"R10-20260616","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3390\/biomedicines9101379","article-title":"A UHPLC-MS\/MS method for therapeutic drug monitoring of aciclovir and ganciclovir in plasma and dried plasma spots.","volume":"9","author":"Pigliasco","year":"2021","journal-title":"Biomedicines"},{"key":"R11-20260616","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1399-3062.2009.00478.x","article-title":"Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.","volume":"12","author":"Pescovitz","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"R12-20260616","doi-asserted-by":"crossref","first-page":"e14141","DOI":"10.1111\/tid.14141","article-title":"Trough ganciclovir concentration as predictor of leukopenia in lung transplant recipients receiving valganciclovir prophylaxis.","volume":"25","author":"Katada","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"R15-20260616","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/INF.0000000000001595","article-title":"Valganciclovir dosing for cytomegalovirus prophylaxis in pediatric solid-organ transplant recipients: a prospective pharmacokinetic study.","volume":"36","author":"Peled","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R16-20260616","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2334-10-2","article-title":"Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+\/R- transplant recipients.","volume":"10","author":"Perrottet","year":"2010","journal-title":"BMC Infect Dis"},{"key":"R17-20260616","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1128\/AAC.02130-15","article-title":"Contribution of population pharmacokinetics to dose optimization of Ganciclovir-Valganciclovir in solid-organ transplant patients.","volume":"60","author":"Padull\u00e9s","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-20260616","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1111\/ajt.17171","article-title":"Antiviral toxicities in pediatric solid organ transplant recipients.","volume":"22","author":"Hayes","year":"2022","journal-title":"Am J Transplant"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001964","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:10Z","timestamp":1781654410000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":15,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001964","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"2026-04-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}